260 related articles for article (PubMed ID: 29233531)
21. Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.
Zannoni GF; Improta G; Pettinato A; Brunelli C; Troncone G; Scambia G; Fraggetta F
J Clin Pathol; 2016 Dec; 69(12):1088-1092. PubMed ID: 27153872
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
23. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
24. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
25. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
[TBL] [Abstract][Full Text] [Related]
26. Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma.
Murakami K; Kanto A; Sakai K; Miyagawa C; Takaya H; Nakai H; Kotani Y; Nishio K; Matsumura N
Mod Pathol; 2021 Nov; 34(11):2071-2079. PubMed ID: 34172890
[TBL] [Abstract][Full Text] [Related]
27. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
[TBL] [Abstract][Full Text] [Related]
28. PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma.
Yamamoto S; Tsuda H; Takano M; Tamai S; Matsubara O
Virchows Arch; 2012 Jan; 460(1):77-87. PubMed ID: 22120431
[TBL] [Abstract][Full Text] [Related]
29. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
[TBL] [Abstract][Full Text] [Related]
30. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Kuroda T; Kohno T
Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
[TBL] [Abstract][Full Text] [Related]
31. PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma.
Jiang G; Huang Z; Zhang S; Wang L
Cancer Invest; 2013 Dec; 31(10):639-44. PubMed ID: 24299208
[TBL] [Abstract][Full Text] [Related]
32. Involvement of Chromatin Remodeling Genes and the Rho GTPases
Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
Front Oncol; 2017; 7():109. PubMed ID: 28611940
[TBL] [Abstract][Full Text] [Related]
33. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Ackroyd SA; Arguello D; Ramos P; Mahdi H; ElNaggar A; Winer I; Holloway R; Krivak T; Jones N; Turner VG; Herzog T; Chu C; Brown J; Mantia-Smaldone G
Gynecol Oncol; 2023 Feb; 169():164-171. PubMed ID: 36333181
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
[TBL] [Abstract][Full Text] [Related]
35. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
[TBL] [Abstract][Full Text] [Related]
36. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
37. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
[TBL] [Abstract][Full Text] [Related]
39. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
40. Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis.
Suda K; Cruz Diaz LA; Yoshihara K; Nakaoka H; Yachida N; Motoyama T; Inoue I; Enomoto T
Cancer Sci; 2020 Aug; 111(8):3000-3009. PubMed ID: 32473611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]